A_DT
new_JJ
variant_JJ
translocation_NN
in_IN
acute_JJ
promyelocytic_JJ
leukemia_NN
:_:
molecular_JJ
characterization_NN
and_CC
clinical_JJ
correlation_NN
._.

Translocation_NN
t_NN
-LRB-_-LRB-
15_CD
;_:
17_CD
-RRB-_-RRB-
-LRB-_-LRB-
q22_NN
;_:
q21_NN
-RRB-_-RRB-
is_VBZ
an_DT
acquired_VBN
clonal_JJ
cytogenetic_JJ
change_NN
present_JJ
in_IN
almost_RB
all_DT
cases_NNS
of_IN
acute_JJ
promelocytic_JJ
leukemia_NN
-LRB-_-LRB-
APL_NN
-RRB-_-RRB-
._.

The_DT
molecular_JJ
genetic_JJ
basis_NN
of_IN
the_DT
translocation_NN
supports_VBZ
its_PRP$
integral_JJ
role_NN
in_IN
pathogenesis_NN
._.

We_PRP
describe_VBP
a_DT
patient_NN
with_IN
APL_NN
in_IN
whom_WP
the_DT
leukemic_JJ
clone_NN
was_VBD
characterized_VBN
by_IN
a_DT
true_JJ
variant_NN
of_IN
the_DT
classical_JJ
t_NN
-LRB-_-LRB-
15_CD
;_:
17_CD
-RRB-_-RRB-
._.

The_DT
patient_NN
whose_WP$
disease_NN
had_VBD
numerous_JJ
atypical_JJ
clinical_JJ
features_NNS
,_,
had_VBD
t_NN
-LRB-_-LRB-
11_CD
;_:
17_CD
-RRB-_-RRB-
-LRB-_-LRB-
q13_CD
;_:
121_CD
-RRB-_-RRB-
._.

The_DT
chromosome_NN
17_CD
breakpoint_NN
was_VBD
localized_JJ
to_TO
intron_NN
2_CD
of_IN
RARA_NN
by_IN
Southern_NN
blotting_NN
,_,
and_CC
there_EX
was_VBD
no_DT
evidence_NN
at_IN
the_DT
molecular_JJ
level_NN
for_IN
rearrangement_NN
at_IN
PML_NN
locus_NN
._.

These_DT
data_NNS
,_,
along_IN
with_IN
previous_JJ
reports_NNS
of_IN
rare_JJ
variant_JJ
translocations_NNS
in_IN
APL_NN
,_,
indicate_VBP
that_IN
while_IN
dysregulation_NN
of_IN
RARA_NN
by_IN
gene_NN
fusion_NN
may_MD
be_VB
essential_JJ
for_IN
the_DT
APL_NN
phenotype_NN
,_,
the_DT
particular_JJ
fusion_NN
partner_NN
may_MD
determine_VB
clinicopathological_JJ
aspects_NNS
,_,
including_VBG
presentation_NN
,_,
response_NN
to_TO
treatment_NN
with_IN
all-trans_JJ
retinoic_JJ
acid_NN
-LRB-_-LRB-
ATRA_NN
-RRB-_-RRB-
,_,
and_CC
prognosis_NN
._.

This_DT
heterogeneity_NN
suggests_VBZ
that_IN
the_DT
variant_JJ
fusion_NN
partners_NNS
of_IN
RARA_NN
in_IN
APL_NN
encode_VBP
factors_NNS
with_IN
properties_NNS
both_CC
common_JJ
to_TO
and_CC
distinct_JJ
from_IN
those_DT
of_IN
PML_NN
._.

Investigation_NN
of_IN
these_DT
factors_NNS
promises_VBZ
to_TO
shed_VB
light_NN
on_IN
the_DT
complex_NN
development_NN
pathways_NNS
involved_VBN
in_IN
the_DT
regulation_NN
of_IN
hematopoiesis_NN
._.

